Combination therapy is not beneficial for certain patients with ovarian cancer
OncLive, MedPage Today highlight UC-led research
OncLive and MedPage Today highlighted research presented by the University of Cincinnati Cancer Center's Thomas Herzog that found a combination therapy of afuresertib and paclitaxel did not lead to better survival outcomes when compared to only treating with paclitaxel in patients with platinum-resistant ovarian cancer.
Afuresertib targets a specific protein called pAKT associated with pathways that support tumor growth, while paclitaxel is a common chemotherapy drug administered to patients with platinum-resistant ovarian cancer.
Herzog presented data from the phase 2 PROFECTA-II/GOG-3044 trial at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. The trial found a median progression-free survival of 4.3 months for patients receiving the combination therapy compared to 4.1 months for those receiving paclitaxel alone.
"Clearly, this was a definitive negative trial for the overall population," said Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center. "However, the biomarker data is provocative, but remember, this is hypothesis-generating only, as it's nonanalytic.
“Effective treatments for [platinum-resistant ovarian cancer] remain limited, thus novel agents are needed,” Herzog added. “Biomarker-driven strategies targeting pAKT may refine patient selection and enhance treatment outcomes in [platinum-resistant ovarian cancer]. However, further validation will be required to confirm this biomarker strategy.”
Read the MedPage Today article.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
PhD student uses engineering to understand cardiovascular system
December 17, 2025
Drawn to the University of Cincinnati for the strong reputation in cardiovascular research and the connections with the UC Medical Center, Shrayesh Manegaonkar is pursuing a PhD in mechanical engineering at the College of Engineering and Applied Science. Recently, he was named Graduate Student Engineer of the Month for his work on biofluid mechanics, aiming to develop better diagnostic tools for cardiovascular diseases.
Ohio looks to fast-track wastewater discharge permits
December 16, 2025
Bradford Mank, James B. Helmer Jr. Professor of Law at the University of Cincinnati, spoke with WVXU for a story about a proposal by the Ohio Environmental Protection Agency to streamline the way wastewater discharge permits are issued to data centers.
Tariff troubles for online shoppers
December 16, 2025
This year’s new regulations on tariffs and customs are leaving holiday shoppers with unexpected fees on some of their purchases, according to recent reporting by WLWT. Associate Dean of Impact and Partnerships for the University of Cincinnati’s Lindner College of Business Charles Sox spoke to WLWT about why shoppers are only just now feeling the impact, despite these policies being in effect for months.